62860 Achievement of treat-to-target thresholds for overall psoriasis response with deucravacitinib: post hoc, subgroup analysis of the randomized, double-blind, placebo-controlled phase 3b/4 PSORIATYK SCALP trial

Document Type

Conference Proceeding

Publication Date

9-1-2025

Publication Title

J Am Acad Dermatol

Abstract

Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. In the phase 3b/4 PSORIATYK SCALP (NCT05478499) trial, deucravacitinib was superior to placebo at Week 16 in patients with moderate to severe scalp psoriasis, including those with less extensive overall body psoriasis.1 This analysis evaluated the efficacy of deucravacitinib in achieving treat-to-target thresholds of overall psoriasis response in patient subgroups based on baseline total BSA involvement. Methods: Adults with moderate to severe scalp psoriasis were randomized 1:2 to oral placebo or deucravacitinib 6 mg once daily. Proportions of patients achieving absolute PASI and BSA thresholds were evaluated at Week 16 in the overall population and in patient subgroups categorized by baseline BSA involvement (3%-10% vs >10%). Analyses are post hoc; P values are nominal. Results: Baseline patient demographics and disease characteristics were similar with placebo (n=51) and deucravacitinib (n=103) (mean PASI, 9.4 vs 10.2; mean BSA, 10.0% vs 10.5%). Higher proportions of patients receiving deucravacitinib versus placebo achieved PASI thresholds ≤1 (29.1% vs 7.8%), ≤2 (47.6% vs 11.8%), ≤3 (61.2% vs 17.6%), ≤4 (68.9% vs 31.4%), and ≤5 (70.9% vs 39.2%) and BSA ≤1% (31.1% vs 7.8%) and ≤3% (55.8% vs 11.4%; P≤0.0027 for all). Deucravacitinib efficacy in achieving treat-to-target thresholds was comparable in BSA 3%-10% and >10% subgroups. Conclusion: Deucravacitinib was efficacious in achieving treat-to-target thresholds in overall psoriasis across a wide range of BSA.

Volume

93

First Page

AB113

Find It @ Sladen

Share

COinS